FDA Inspection 1301186 — ImpactLife
The FDA completed an inspection of ImpactLife on February 2, 2026 in Cedar Rapids, IA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Biologics.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- February 2, 2026
- Fiscal Year
- 2026
- Product Type
- Biologics
- Project Area
- Blood and Blood Products
- Location
- Cedar Rapids, IA (United States)